Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes
GlobeNewswire - Mon Mar 31, 7:00PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000(R) and Russell 3000(R) Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
GlobeNewswire - Wed Mar 26, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013.
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Revance Therapeutics to Release Fourth Quarter and Full Year 2013 Financial Results and Host Conference Call on Wednesday, March 26, 2014
GlobeNewswire - Wed Mar 12, 3:01PM CDT
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release fourth quarter and full year 2013 financial results on Wednesday, March 26, 2014 after the close of market. Revance will host a conference call and a live Internet webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business update.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 3:28PM CST
The beginning of the year swoon has decisively been put in the rearview mirror, with the broad-based S&P 500 launching itself to a new all-time high earlier this week on easing geopolitical fears. For skeptics like me, that's an opportunity to...
Revance to Add Angus C. Russell as Chairman to Its Board of Directors
GlobeNewswire - Wed Mar 05, 7:00AM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Angus C. Russell has been appointed as Chairman to its Board of Directors, effective immediately.
Revance Therapeutics, Inc. Announces Participation in Cowen 34th Annual Health Care Conference
GlobeNewswire - Wed Feb 19, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Cowen 34th Annual Health Care Conference in Boston.
Revance Therapeutics Inc concludes USD110m IPO, including underwriters' over-allotment option
M2 - Wed Feb 12, 3:40AM CST
Biopharmaceutical company Revance Therapeutics Inc (NasdaqGS :RVNC) reported on Tuesday the completion of its initial public offering of 6,900,000 shares of common stock at a public offering price of USD16.00 per share.
Revance Therapeutics, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Tue Feb 11, 3:05PM CST
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the closing of its initial public offering of 6,900,000 shares of common stock at a public offering price of $16.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock at the same price to cover over-allotments. Gross proceeds from the sale of the shares is approximately $110 million. The net proceeds from the sale of the shares, after deducting the underwriters' discount and other estimated offering expenses will be approximately $98.7 million.
IPO roundup: 5 companies start trading Thursday
AP - Thu Feb 06, 3:45PM CST
NEW YORK (AP) — Five companies began trading publicly on Thursday as the market for initial public offerings continued to go strong following a busy 2013. Three of the five are pharmaceutical companies.
Revance Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Wed Feb 05, 8:15PM CST
Revance Therapeutics, Inc. (Revance), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "RVNC" on February 6, 2014. In addition, Revance has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on February 11, 2014, subject to customary closing conditions.